Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

DECLARATION is a Phase 3, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of VYD2311 in the prevention of COVID ...
PharmTech

Innovation and Market Exclusivity in the EU

The revised EU pharmaceutical policy maintains eight-year data protection but reduces market protection to one year, ...

Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

NEW HAVEN, Conn., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for VYD2311, an ...

Unpacking claim Trump's name was redacted by DOJ from Epstein document after release

There was no proof the DOJ redacted the document after posting it. In fact, there was a copy of it on the DOJ website that ...